RxDoctor Payments Data

Rainbow Chung-Ou, MD

Family Medicine · Chino, CANPI 1811282650

Payments from drug & device makers

$3,108in general payments, 2019–2025

Across 149 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$498
  • GSK$331
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$308
  • Merck$306
  • Lilly USA, LLC$303
  • AstraZeneca$207
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,108100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,108 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$45,937
Medicare patients
120
Services billed
622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin47$60,261
EliquisApixaban50$55,049
JanuviaSitagliptin Phosphate38$31,896
OzempicSemaglutide26$26,564
FarxigaDapagliflozin Propanediol17$23,746
Diclofenac Sodium86$21,151
XareltoRivaroxaban16$20,110
LinzessLinaclotide18$16,950
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$11,086
EntrestoSacubitril/Valsartan14$10,377
BelsomraSuvorexant16$7,353
Breo ElliptaFluticasone/Vilanterol17$6,640
Atorvastatin Calcium445$4,959
Risedronate Sodium17$4,690
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$4,089

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$85$60,26147 claims
PfizerEliquis$498$55,04950 claims
MerckJanuvia, Belsomra$306$39,25054 claims
Novo NordiskOzempic$17$26,56426 claims
AstraZenecaFarxiga$207$23,74617 claims
GSKTrelegy Ellipta, Breo Ellipta$331$17,72533 claims
AbbVieLinzess$38$16,95018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Chino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →